Treatment-Resistant Depression: What It Means — and What Still Works

First: the label is a doorway, not a verdict

The phrase sounds like a dead end, and it's the opposite. "Treatment-resistant" is how medicine formally recognizes that standard antidepressants weren't enough for you — and that recognition is precisely what unlocks the next tier of options and their insurance coverage. If you've given two or more antidepressants a fair trial (adequate dose, adequate duration) without sufficient relief, you likely meet the definition — and the conversation below is about you.

Why medications sometimes aren't enough

Antidepressants primarily work through the brain's monoamine systems, and for many people that's the right lever. But depression isn't one biology; when the first lever doesn't move things, pulling it harder — another similar medication, then another — often produces the discouraging cycle TRD patients know well. The treatments in the next tier matter because they pull different levers: direct circuit stimulation, the glutamate system, different mechanisms entirely. Non-response to antidepressants does not predict non-response to these.

The TRD toolkit, honestly described

TMS therapy. FDA-cleared, non-medication, delivered as brief daily outpatient sessions of focused magnetic pulses over several weeks — no sedation, no downtime, driving yourself throughout. The commitment is the daily calendar; the trade is a treatment with a well-documented safety profile and no systemic medication effects. Commonly insurance-covered for TRD, including Medicare.

SPRAVATO® (esketamine). FDA-approved specifically for treatment-resistant depression (and for depressive symptoms in adults with MDD with acute suicidal thoughts or actions). Works through the glutamate system — a genuinely different mechanism from standard antidepressants — administered in certified centers under a federally required safety program, with monitoring after each dose. Commonly insurance-covered when TRD criteria are met.

Medically supervised ketamine therapy. For appropriate patients, generic ketamine offers a related mechanism as in-clinic, medically supervised treatment; its depression use is off-label, so it's typically self-pay — a factor we're upfront about in planning.

Smarter medication strategy. Sometimes the medication chapter isn't finished — it's been mismanaged: inadequate doses, too-short trials, untried augmentation approaches, or combinations never explored. A physician-led review of the full medication history is where every TRD evaluation should start, because occasionally the answer is a strategy nobody tried, and always it shapes which advanced option fits.

And honesty about ECT. For certain severe presentations, electroconvulsive therapy remains an important hospital-based option; our TMS vs. ECT comparison covers that decision honestly.

How the path actually runs here

Free consultation → physician-led psychiatric evaluation (including the medication-history review above) → benefits verification and prior authorization handled by our team → a treatment plan you understand, with the next step already mapped if the first doesn't deliver enough. Because TMS, SPRAVATO®, supervised ketamine, and medication management all live under one roof, sequencing between them is a conversation — not a new provider search. Serving Denver, Aurora, and the Front Range; most major insurance accepted, including Medicare.

720-500-7873 — free consultations, no referral required. Deeper reading: TMS therapy, SPRAVATO®, how much ketamine therapy costs.

Frequently asked questions